Identification of potential driver genes in human liver carcinoma by genomewide screening.

Genomic copy number aberrations and corresponding transcriptional deregulation in the cancer genome have been suggested to have regulatory roles in cancer development and progression. However, functional evaluation of individual genes from lengthy lists of candidate genes from genomic data sets presents a significant challenge. Here, we report effective gene selection strategies to identify potential driver genes based on systematic integration of genome scale data of DNA copy numbers and gene expression profiles. Using regional pattern recognition approaches, we discovered the most probable copy number-dependent regions and 50 potential driver genes. At each step of the gene selection process, the functional relevance of the selected genes was evaluated by estimating the prognostic significance of the selected genes. Further validation using small interference RNA-mediated knockdown experiments showed proof-of-principle evidence for the potential driver roles of the genes in hepatocellular carcinoma progression (i.e., NCSTN and SCRIB). In addition, systemic prediction of drug responses implicated the association of the 50 genes with specific signaling molecules (mTOR, AMPK, and EGFR). In conclusion, the application of an unbiased and integrative analysis of multidimensional genomic data sets can effectively screen for potential driver genes and provides novel mechanistic and clinical insights into the pathobiology of hepatocellular carcinoma.

[1]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[2]  Derek Y. Chiang,et al.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.

[3]  I. Ben-Sahra,et al.  The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level , 2008, Oncogene.

[4]  Jung-Hwan Yoon,et al.  Gene Expression–Based Recurrence Prediction of Hepatitis B Virus–Related Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.

[5]  G. Tortora,et al.  Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs , 2008, British Journal of Cancer.

[6]  Jane Fridlyand,et al.  Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer , 2007, Hepatology.

[7]  S. Hirohashi,et al.  Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. , 2007, Gastroenterology.

[8]  S. Lindquist,et al.  Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis , 2007, Cell.

[9]  Jeffrey S. Morris,et al.  Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma , 2007, Cancer.

[10]  Y. Abe,et al.  Human scribble accumulates in colorectal neoplasia in association with an altered distribution of beta-catenin. , 2007, Human pathology.

[11]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[12]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[13]  R. Tibshirani,et al.  Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. , 2007, Blood.

[14]  Deepak Kolippakkam,et al.  Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth. , 2007, Cancer research.

[15]  V. Mazzaferro,et al.  Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.

[16]  A. Whittemore,et al.  Multiple regions within 8q24 independently affect risk for prostate cancer , 2007, Nature Genetics.

[17]  Wen-Hui Su,et al.  OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci , 2006, Nucleic Acids Res..

[18]  亀井 義明.  Human scribble accumulates in colorectal neoplasia in association with an altered distribution of β-catenin , 2007 .

[19]  D. Pinkel,et al.  Regional copy number–independent deregulation of transcription in cancer , 2006, Nature Genetics.

[20]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[21]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[22]  M. Rattray,et al.  A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. , 2006, Gastroenterology.

[23]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[24]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[25]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[26]  M. Sherman,et al.  Heat Shock Transcription Factor HSF1 Plays a Critical Role in Cell Migration via Maintaining MAP Kinase Signaling , 2006, Cell cycle.

[27]  L. Chin,et al.  High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. , 2006, Cancer cell.

[28]  S. Thorgeirsson,et al.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.

[29]  Howard Y. Chang,et al.  Genetic regulators of large-scale transcriptional signatures in cancer , 2006, Nature Genetics.

[30]  P. Philip,et al.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Rui Li,et al.  An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma , 2005, Oncogene.

[32]  P. Schirmacher,et al.  Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade – results of an explorative CGH meta-analysis , 2005, British Journal of Cancer.

[33]  Jane Fridlyand,et al.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. , 2005, Human molecular genetics.

[34]  M. Torbenson,et al.  mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms , 2004, Clinical Cancer Research.

[35]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[36]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[37]  Homin K. Lee,et al.  Coexpression analysis of human genes across many microarray data sets. , 2004, Genome research.

[38]  X. Wang,et al.  Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning , 2003, Nature Medicine.

[39]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.